Monthly Archives: December 2017

The SVP, GC & Sec of JM Smucker (NYSE: SJM) is Selling Shares

Yesterday, the SVP, GC & Sec of JM Smucker (NYSE: SJM), Jeannette Knudsen, sold shares of SJM for $199K. Based on JM Smucker’s latest earnings report for the quarter ending October 31, the company posted quarterly revenue of $1.92 billion

The VP, Corporate Secretary of Access National Corp is Exercising Options

Today, the VP, Corporate Secretary of Access National Corp, Sheila Linton, exercised options of Access National Corp for $11.41K. The options were close to expired and Sheila Linton retained stocks. Following Sheila Linton’s last ANCX Buy transaction on January 25,

The VP & CFO of Pendrell Corp (NASDAQ: PCO) is Selling Shares

Today, the VP & CFO of Pendrell Corp (NASDAQ: PCO), Steve Ednie, sold shares of PCO for $29.48K. In addition to Steve Ednie, one other PCO executive reported Sell trades in the last month. Based on Pendrell Corp’s latest earnings

What Did This CEO Just Do with Personal Shares of DXP Enterprises (NASDAQ: DXPE)?

Today, the Chairman & CEO of DXP Enterprises (NASDAQ: DXPE), David Little, sold shares of DXPE for $398.3K. This is Little’s first Sell trade following 3 Buy transactions. In addition to David Little, one other DXPE executive reported Sell trades

Canaccord Genuity Reaffirms Their Hold Rating on Pacira Pharmaceuticals

Canaccord Genuity analyst Dewey Steadman maintained a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX) today and set a price target of $42. The company’s shares opened today at $45.45. Steadman wrote: “We’re looking for more than two months of data

Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (NASDAQ: ATRA), United Therapeutics (NASDAQ: UTHR) and ANI Pharmaceuticals Inc (NASDAQ: ANIP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atara Biotherapeutics (NASDAQ: ATRA), United Therapeutics (NASDAQ: UTHR) and ANI Pharmaceuticals Inc (NASDAQ: ANIP). Atara Biotherapeutics (NASDAQ: ATRA) Canaccord Genuity analyst John Newman assigned a